Point72 Asset Management’s Teva Pharmaceuticals TEVA Stock Holding History

Point72 Asset Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$13.5M	Buy	399,200 +15,600	+4%	+$520K	0.01%	1098
2026 Q1	$11.6M	Buy	+383,600	New	+$12.3M	0.01%	1145
2025 Q3	–	Sell	-1,900	Closed	-$31.8K	–	2674
2025 Q2	$31.8K	Sell	1,900 -33,200	-95%	-$536K	﹤0.01%	2116
2025 Q1	$539K	Sell	35,100 -130,100	-79%	-$2.32M	﹤0.01%	1613
2024 Q4	$3.64M	Buy	+165,200	New	+$3.01M	0.01%	1046
2024 Q1	–	Sell	-31,000	Closed	-$324K	–	2613
2023 Q4	$324K	Hold	31,000	–	–	﹤0.01%	1681
2023 Q3	$316K	Hold	31,000	–	–	﹤0.01%	1638
2023 Q2	$233K	Hold	31,000	–	–	﹤0.01%	1413
2023 Q1	$274K	Hold	31,000	–	–	﹤0.01%	1386
2022 Q4	$283K	Buy	+31,000	New	+$270K	﹤0.01%	1217
2022 Q3	–	Sell	-63,300	Closed	-$476K	–	1729
2022 Q2	$476K	Buy	+63,300	New	+$551K	﹤0.01%	1197
2018 Q4	–	Sell	-600,000	Closed	-$12.9M	–	1200
2018 Q3	$12.9M	Buy	+600,000	New	+$13.9M	0.05%	410

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Point72 Asset Management's TEVA Position: Q2 2026 in Review

Point72 Asset Management reduced its Teva Pharmaceuticals (TEVA) stake by 6.3% in Q2 2026, selling an estimated $2.36M and leaving 1,059,778 shares worth $35.9M. The position accounts for 0.04% of the portfolio, ranked #580.

Point72 Asset Management first reported a position in TEVA in Q2 2014 and has held it in 27 quarters since. The position peaked at $90.7M in Q2 2018. 675 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

Point72 Asset Management held 1,059,778 shares of Teva Pharmaceuticals worth $35.9M as of Q2 2026.
Point72 Asset Management sold 70,729 Teva Pharmaceuticals shares in Q2 2026, an estimated $2.36M.
Teva Pharmaceuticals made up 0.04% of Point72 Asset Management's portfolio in Q2 2026, its #580 holding.
Point72 Asset Management first reported a position in Teva Pharmaceuticals in Q2 2014 and has held it in 27 quarters since.
Point72 Asset Management's Teva Pharmaceuticals position peaked at $90.7M in Q2 2018.
675 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.